Automation Workflow for Companion Diagnostic (CDx) Co-Development Submission Alignment

Manual tracking of two parallel regulatory timelines creates a high risk of misalignment, where a drug is approved but its required diagnostic is not. A custom agentic workflow continuously monitors milestone progress for both products in systems like Veeva RIM, flags schedule drift exceeding a pre-defined threshold (e.g., >2 weeks), and triggers automated alerts to program managers. This proactive synchronization prevents the costly scenario of a delayed launch or the need for a bridging study.

Regulators meticulously compare claims and data between the drug and diagnostic submissions. A custom workflow deploys validation agents that parse draft documents (CSRs, analytical validation reports) from repositories like SharePoint or Veeva Vault. Using retrieval-augmented generation (RAG) over submission guidelines, agents flag discrepancies in key parameters—such as claimed biomarker prevalence, cut-off values, or patient population definitions—for immediate review by the joint development team before filing.

Agency questions often require a coordinated response from both drug and diagnostic teams. An orchestrated workflow automatically routes incoming Regulatory Questions (RQs) from portals like the FDA ESG to the appropriate functional agents. These agents retrieve relevant data from connected clinical data warehouses and diagnostic platforms, draft aligned response sections, and compile them into a single, consistent response package. This cuts weeks from the response cycle, maintaining review momentum.

Co-development requires assembling two interdependent submission packages. A custom orchestration layer uses agents to monitor the 'ready' status of shared components (e.g., clinical study data, biomarker analysis) in source systems. Once approved, agents automatically compile these components into the appropriate sections of both the drug (e.g., eCTD Module 2.7.4) and diagnostic (e.g., 510(k)/PMA technical section) dossiers, applying respective formatting templates. This eliminates duplicate manual extraction and formatting work.

Regulators expect a clear rationale for diagnostic claims and lock-in decisions. The workflow embeds governance by logging all automated cross-checks, evidence retrievals, and alignment actions. Every agent-triggered alert or compiled document is recorded with a timestamp, data source, and business rule invoked. This generates an immutable, queryable audit trail within the RIM system, providing ready defensibility during agency inspections or pre-submission meetings.

A practical build uses LangGraph or a similar framework to orchestrate specialized agents for timeline monitoring, document parsing, and validation. These agents integrate via APIs or RPA into the drug team's clinical systems (e.g., Oracle Clinical) and the diagnostic team's quality systems (e.g., LIMS, QMS). A central 'orchestrator' agent maintains the state of the joint submission, routing exceptions to a human-in-the-loop dashboard in ServiceNow or Jira for review. Rollout starts with a pilot on one shared module (e.g., clinical evidence) before scaling.

This core agent continuously monitors the status of evidence generation and key submission documents for both the therapeutic and diagnostic. It connects to Veeva Vault, LIMS, and clinical data warehouses to track protocol amendments, analytical validation reports, and statistical analysis plans. By maintaining a real-time registry of document versions and approval states, it provides a single source of truth for co-development progress, eliminating manual status calls and spreadsheet tracking.

A specialized validation agent performs cross-referential analysis between drug and diagnostic data packages. It parses clinical study reports, labeling drafts, and analytical performance data to flag mismatches in patient population definitions, claimed clinical utility, or statistical significance thresholds. Using RAG over historical deficiency letters, it identifies high-risk inconsistencies that could trigger regulatory questions, routing them to a joint review queue for resolution before submission.

This orchestrator agent models the interdependent timelines of drug and diagnostic development milestones. Ingesting data from project management tools (e.g., Planisware, Smartsheet) and regulatory calendars, it simulates the impact of delays in one program on the other. It automatically alerts program managers of schedule drift, recommends compensatory actions, and updates integrated submission plans to protect synchronized filing targets for FDA CDRH/CDER or EMA parallel reviews.

Upon receipt of agency questions, this multi-agent system coordinates the response process across both development teams. It parses inquiries from FDA/EMA portals, classifies them as drug, diagnostic, or joint issues, and retrieves relevant evidence from respective document repositories. It drafts aligned response narratives, manages a consolidated review cycle, and ensures final responses are formatted and submitted cohesively, preventing contradictory or siloed communications.

This component automates the alignment of Chemistry, Manufacturing, and Controls (CMC) data for the diagnostic with the drug's product quality reviews. It extracts specifications, stability data, and assay performance characteristics from LIMS and QMS systems, mapping them to the structure of eCTD Module 3. It ensures that diagnostic manufacturing changes are assessed for potential impact on clinical claims, generating comparability protocols and reports for pre-submission meetings.

The control plane provides a unified dashboard showing alignment health scores, open discrepancy tickets, and milestone confidence. Every agent action—from document check-in to discrepancy flag—is logged to an immutable audit trail in a system like AWS QLDB or Azure SQL. This creates a defensible record of due diligence for regulators, demonstrating proactive co-development management. The dashboard enables executive go/no-go decisions based on live readiness metrics for the combined submission package.